ATE452651T1 - Orale impfstoff-zusammensetzung - Google Patents

Orale impfstoff-zusammensetzung

Info

Publication number
ATE452651T1
ATE452651T1 AT99940438T AT99940438T ATE452651T1 AT E452651 T1 ATE452651 T1 AT E452651T1 AT 99940438 T AT99940438 T AT 99940438T AT 99940438 T AT99940438 T AT 99940438T AT E452651 T1 ATE452651 T1 AT E452651T1
Authority
AT
Austria
Prior art keywords
microparticles
oral vaccine
vaccine formulations
less
vaccine composition
Prior art date
Application number
AT99940438T
Other languages
German (de)
English (en)
Inventor
David Brayden
Original Assignee
Merrion Res Iii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Res Iii Ltd filed Critical Merrion Res Iii Ltd
Application granted granted Critical
Publication of ATE452651T1 publication Critical patent/ATE452651T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT99940438T 1998-09-01 1999-08-31 Orale impfstoff-zusammensetzung ATE452651T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9875998P 1998-09-01 1998-09-01
PCT/IE1999/000086 WO2000012124A1 (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Publications (1)

Publication Number Publication Date
ATE452651T1 true ATE452651T1 (de) 2010-01-15

Family

ID=22270760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940438T ATE452651T1 (de) 1998-09-01 1999-08-31 Orale impfstoff-zusammensetzung

Country Status (7)

Country Link
EP (2) EP1107782B1 (https=)
JP (1) JP4601823B2 (https=)
AT (1) ATE452651T1 (https=)
AU (1) AU5441199A (https=)
CA (1) CA2341352C (https=)
DE (1) DE69941848D1 (https=)
WO (1) WO2000012124A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
DE60319073T2 (de) * 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
FR2857592B1 (fr) * 2003-07-18 2006-02-24 Sod Conseils Rech Applic Nouveau procede de preparation de microparticules
EP1872793B1 (en) * 2005-04-20 2012-10-10 Mitsuru Akashi Polyamino acid for use as adjuvant
JP4621218B2 (ja) * 2007-02-09 2011-01-26 有限会社バイオ研 Ｔｈ１誘導剤及びその製造方法
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
ATE129159T1 (de) * 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
EP0678035B9 (en) 1993-01-08 2006-12-13 Csl Limited Vaccine preparations
ES2182850T3 (es) 1993-10-22 2003-03-16 Genentech Inc Procedimientos y composiciones para la microencapsulacion de adyuvantes.
KR100372375B1 (ko) 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
JP3747077B2 (ja) * 1994-04-28 2006-02-22 武田薬品工業株式会社 百日咳菌由来感染防御成分の分離取得方法
EP0805678B1 (en) * 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
CA2341352A1 (en) 2000-03-09
EP2168593A1 (en) 2010-03-31
WO2000012124A1 (en) 2000-03-09
CA2341352C (en) 2013-01-08
EP1107782A1 (en) 2001-06-20
JP4601823B2 (ja) 2010-12-22
JP2002523470A (ja) 2002-07-30
AU5441199A (en) 2000-03-21
EP1107782B1 (en) 2009-12-23
DE69941848D1 (de) 2010-02-04

Similar Documents

Publication Publication Date Title
ATE452651T1 (de) Orale impfstoff-zusammensetzung
FI935396A7 (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
NO952077D0 (no) Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri
WO1997001640A3 (en) Vaccines against hepatitis c
IL126357A (en) Phenyl-substituted cyclic ketoenols, processes for their preparation and insecticide, acaricide and herbicide compositions containing them
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
ES2191979T3 (es) Sistema de administracion de acido linoleico conjugado en preparaciones cosmeticas.
FI885109A0 (fi) Foerfarande foer solidifikation och inkapsling med anvaendning av kaern-skalpolymerpartiklar.
DE69807441D1 (de) Orale zusammensetzung mit verbesserter aufnahme
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
AU635049B2 (en) Encapsulation method, microelectronic devices made therefrom, and heat curable compositions
BR9304175A (pt) Formulação de adesivo de monômero de cianoacrilato, formulação estabilizada de adesivo de cianoacrilato, e composição de polímero de cianoacrilato
DE19581750T1 (de) Strahlungshärtbare lösbare Organopolysiloxanzusammensetzungen
JP2002523471A5 (https=)
DK0904063T3 (da) Fremgangsmåde til fremstilling af mikropartikler
JP2002523470A5 (https=)
FI972054A0 (fi) Immunogeenisiä koostumuksia
IT1281220B1 (it) Imballaggio per prodotti astiformi, in particolare come sigarette, o simili, nonche' metodo e dispositivo per la fabbricazione dello stesso
EP0804924A3 (en) Skin protection, fragrance enhancing and vitamin delivery composition
FR2661070B1 (fr) Compositions insecticides a base de chrysanthemate de 2,4-dioxo-1-(2-propynyl) imidazolidine-3-ylmethyle.
TW223648B (en) Vinyloxygruppen aufweisende siloxancopolymere, deren herstellung undverwendung (2)
EP0852246A3 (en) Aromatic polyamide and fullerene containing compositions, moulded articles therefrom
CA2470622A1 (en) Sunscreen composition comprising chlorphenesin
EE200100309A (et) Suukaudne vaktsiinikompositsioon diarröad põhjustava enterotoksigeense E. coli vastu
IT9048407A0 (it) Procedimento di regolazione antibloccaggio e sistema antibloccaggio per la esecuzione del procedimento, in particolare per veicoli da altavelocita'.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties